Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $60.89 Average Price Target from Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given an average recommendation of “Hold” by the eleven ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $60.8889.

IMCR has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Needham & Company LLC upped their price objective on shares of Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, UBS Group set a $55.00 target price on Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th.

Insider Buying and Selling at Immunocore

In other news, insider Leger Tina Amber St sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $32,350.00. Following the completion of the sale, the insider directly owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. This represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider owned 5,859 shares in the company, valued at approximately $189,538.65. This trade represents a 50.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 19,137 shares of company stock worth $619,082. 10.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. purchased a new stake in shares of Immunocore in the fourth quarter valued at about $47,000. XTX Topco Ltd purchased a new position in shares of Immunocore during the fourth quarter worth about $763,000. Voloridge Investment Management LLC acquired a new position in Immunocore in the 4th quarter valued at about $978,000. Vestal Point Capital LP acquired a new position in Immunocore in the 4th quarter valued at about $20,305,000. Finally, Virtus Investment Advisers LLC raised its stake in Immunocore by 48.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 18,569 shares of the company’s stock valued at $645,000 after acquiring an additional 6,097 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

IMCR stock opened at $28.56 on Friday. The business has a 50 day moving average price of $31.32 and a 200 day moving average price of $33.48. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -40.80 and a beta of 0.83. Immunocore has a fifty-two week low of $27.44 and a fifty-two week high of $40.71.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.60) earnings per share for the quarter. The company had revenue of $104.48 million for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%. Equities research analysts anticipate that Immunocore will post -0.97 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.